chrisvoncsefalvay/vaers-outcomes huggingface dataset:
stomach issues; headache; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache). At the time of the report, ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, SARS-CoV-2 test: negative (Negative) negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache). At the time of the report, ABDOMINAL DISCOMFORT (stomach issues) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, SARS-CoV-2 test: negative (Negative) negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.  Company comment: Very limited information regarding this events has been provided at this time. Company assessed the events to be unlikely related to company product.; Reporter's Comments: Very limited information regarding this events has been provided at this time. Company assessed the events to be unlikely related to company product.
INJECTION SITE ITCHY; CHILLS; PAIN/SORENESS IN LEFT ARM AFTER SHORT; This spontaneous report received from a patient concerned a 45 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included high blood pressure, thyroid problems, and seasonal allergies. The patient experienced drug allergy when treated with acetylsalicylic acid. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, and batch number: 202A21A expiry: UNKNOWN) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. Concomitant medications included lisinopril for high blood pressure, and levothyroxine sodium for thyroid problems. On 11-APR-2021, the subject experienced pain/soreness in left arm after short. On 12-APR-2021, the subject experienced chills. On 13-APR-2021, the subject experienced injection site itchy. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from pain/soreness in left arm after short, and the outcome of chills and injection site itchy was not reported. This report was non-serious.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39-year-old male patient received bnt162b2 (BNT162B2), on 15Jun2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 37 years for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19; patient was treated with PAXLOVID.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
76y.o. male with a PMH significant for CKD stage V s/p kidney transplant in 2020 on prograf and cellcept, OSA on CPAP since July 2022, CAD s/p triple stent placement in 2022, HTN, and HLD who presented to facility on 9/28/2022 with a chief complaint of cough and fever. Patient's symptoms of non-productive cough and fever started one month ago at which point he was covid19 +. Pt found to be leukopenic, hyponatremic, and  with chest xray showing RLL opacity suspicious for pneumonia. CT chest: Extensive polycystic changes of the visualized native kidneys. Bilateral groundglass airspace opacities, greatest in the right lower lobe. These findings can be see with of atypical pneumonia such as Covid. Patient was treated for CAP pneumonia with ceftriaxone and azithromycin. He was transitioned to levoquin for a total of 7 days. Transplant team worked incoordination with IM team to treat and evaluate patient. Patient was initially hyponatremic, which improved with fluid restriction and liberalization of salt intake. Patient developed AKI, that was monitored by transplant team; improved with some IVF. Patient also provided 1x Granix for leukopenia; which improved immediately. Patient to follow up with transplant team on discharge with labwork. Patient provided albuterol inhaler, breo, and zyrtec to help alleviate symptoms with close follow up with PCP as patient does not need extended course of these medications. Patient also underwent 2d echo as murmur noted; showed persistent mild AS. Patient to continue follow up with cardiology.
The pt was inadvertently vaccinated and subsequently turned red in color all over his body. He experienced tingling in his legs and feet and became clammy. The pt was observed in the physician's office.
arm that she got the shot in is extremely hot to the touch; arm is swollen; arm is bright red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (arm that she got the shot in is extremely hot to the touch), VACCINATION SITE SWELLING (arm is swollen) and VACCINATION SITE ERYTHEMA (arm is bright red) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Chemotherapy since an unknown date.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (arm that she got the shot in is extremely hot to the touch), VACCINATION SITE SWELLING (arm is swollen) and VACCINATION SITE ERYTHEMA (arm is bright red). At the time of the report, VACCINATION SITE WARMTH (arm that she got the shot in is extremely hot to the touch), VACCINATION SITE SWELLING (arm is swollen) and VACCINATION SITE ERYTHEMA (arm is bright red) outcome was unknown.            No concomitant medications were reported.  No treatment medications were reported.  It was reported that patient is currently on chemotherapy regimen. And she didn't have these events with the first two doses.
Adverse event: Vaccine was administered 3 weeks after beyond use date and is less effective. Treatment: Pt returning to our office for additional vaccine based on Pfizer and state recommendations.
This spontaneous report was received from a pharmacist and refers to a 43-year-old patient of unknown gender. The patient's medical history and concurrent condition were not reported. On 18-SEP-2015, the patient was vaccinated with a dose of ZOSTAVAX (inappropriate schedule of drug administration). No adverse effects were reported. No product quality complaint (PQC) was filed for ZOSTAVAX. Additional information has been requested.
6MAY92 8PM t104-105 R; had APAP beginning prior to vax; screamed 8PM-6AM & was stiff & shaking; 8AM mom noticed rash on trunk; Had explosive diarrhea during fever; did not take to ER; Seen by MD 7MAY92 by appt dx rxn to DTP & viral rash;
pt recvd vax & devel hypotension, an elevation in liver funct tests, mild disseminated intravascular coagulation; pt was adm to hosp & recovered following treatment;
Emergency dental surgery; caller received the 1st Moderna vaccine on 20Apr2021 and didn't receive 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of DENTAL OPERATION (Emergency dental surgery) and PRODUCT DOSE OMISSION ISSUE (caller received the 1st Moderna vaccine on 20Apr2021 and didn't receive 2nd dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     Concurrent medical conditions included Leukemia and Immunocompromised.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (caller received the 1st Moderna vaccine on 20Apr2021 and didn't receive 2nd dose). On an unknown date, the patient experienced DENTAL OPERATION (Emergency dental surgery). The patient was treated with Surgery for Dental operation. On 20-May-2021, PRODUCT DOSE OMISSION ISSUE (caller received the 1st Moderna vaccine on 20Apr2021 and didn't receive 2nd dose) had resolved. At the time of the report, DENTAL OPERATION (Emergency dental surgery) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. Treatment information was not provided by reporter.  company comment:Very limited information regarding this event Dental Operation has been provided at this time.  Further information has been requested. The event Product Dose Omission Issue was not accompanied by any adverse event. A causality assessment is not applicable.; Sender's Comments: Very limited information regarding this event Dental Operation has been provided at this time.  Further information has been requested. The event Product Dose Omission Issue was not accompanied by any adverse event. A causality assessment is not applicable.
Crying for 2 hours and 45 minutes; 2 to 3 days later, had her 1st seizure. Stopped sleeping all night. Made choking sounds when she slept. When I finally saw a seizure (grand mal) from start to finish. Took her to doctor and 1 week later was put on meds.
Administered expired vaccine (GARDASIL - 12/4/2015). No reaction to expired vaccine.
Patient developed fatigue and was generally not feeling well and then developed a fever of 102 with nausea and dry heaving.
Left shoulder pain, stabbing and cramping pain in arms, legs, and occasional back area. Sometimes will interrupt sleep.
herpes returns more frequently than before; This non-serious case was reported by a consumer via call center representative and described the occurrence of herpes virus infection in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced herpes virus infection (Verbatim: herpes returns more frequently than before). The patient was treated with valaciclovir (Valacyclovir). The outcome of the herpes virus infection was not reported.   It was unknown if the reporter considered the herpes virus infection to be related to Shingrix.  It was unknown if the company considered the herpes virus infection to be related to Shingrix.   Additional Information: GSK Receipt Date: 23-JUN-2023 The Pfizer Covid vaccine negated the Shingrix shots. The pharmacy said that he/she could not gave any more Shingrix shots.  Now herpes returned more frequently than before.  He/she could take Valacyclovir but only once he/she sense a bout was starting. The Shingrix was such a welcome improvement.  The reporter wanted to know what did you think he/she might be able to take it again and were you aware of this side effect from the pfizer vaccine.
The Yellow Fever Vaccine was administered subcut in pt's right arm on 1/20/2010. After 48 hours, pt. stated that injection site was erythematous and hot to the touch, with a red ring around the swollen injection site. The swelling was approximately 5 inches by 3 inches. Pt. saw her Dr. on 1/25/11, who diagnosed cellulitis and prescribed Keflex 500 mg. qid. Pt. said that swelling and discomfort have subsided but that right hand is swollen. She was to have a follow up appt. with her Dr. this afternoon.
Likely seizure-taken to ER and less responsive. Examined and observed. No more seizure.
I was having diarrhea like yellowish liquid and it was really pungent smell; body aches; bumps in her right arm; nausea; fever; diarrhea; chills; headache; This is a spontaneous report received from a contactable consumer (Patient). A 46-year-old female patient received BNT162B2 (PFIZER-BIONTEHC COVID-19 VACCINE, Batch/Lot Number: FC3180), Solution for injection, via an unspecified route of administration, administered in Arm Left on 20Aug2021 (at the age of 46-year-old) as single dose for covid-19 immunisation. Medical history was reported as none. There were no concomitant medications. On 20Aug2021, at noon. 1 hour after the vaccine the patient experienced nausea, fever, diarrhea, chills, headache, was having diarrhea like yellowish liquid and it was really pungent smell, body aches and bumps in her right arm. She received yesterday at noon the first shot and 1 hour after the vaccine she started to feel the side effects like nausea, diarrhea, fever, body ache, chills, headache and bumps in her right arm. She received the vaccine in her left arm. The outcome of event was not recovered.
Patient with 2 COVID vaccines who admitted with COVID complications and positive COVID PCR.  Provider d/c note:  "Hospital Course: Young man with prior traumatic tracheostomy who recently underwent tracheal reconstruction surgery and was recently placed on anticoagulation for superficial thrombosis presents with tracheostomy bleeding and dyspnea from partial airway obstruction.  He was admitted to the PCU and treated with cool mist and nebulized therapy; his anticoagulation was stopped.  He was found to have acute COVID; CXR and CT chest were negative for PE or respiratory disease.  Given his airway threatening bleeding on anticoagulation for superficial thrombosis without evidence of deep thrombosis, it was recommended that his anticoagulation be stopped.  Patient improved and requested discharge to home to follow up with ENT in the next several days."
Fever - 102F starting 12 hours after vaccine and subsiding 48 hours after. Body aches - starting day after and ending after 48 hours. Vertigo (spinning) starting 10 days after shot and continuing off and on to this day. Dizziness - starting 10 days after shot and still a problem daily. Nausea - with episodes of vertigo. Feeling off balance - same time frame as dizziness Tinnitus - same time frame as dizziness - constant. Blurry vision - same time frame, 3-4 days a week. Increased eye floaters - same time frame. Brain fog - comes and goes. Motion sickness triggered by riding in a car or side motion in my field of vision. Sensitivity to sound. Sensitivity to light.
Site: Bruising at Injection Site-Mild, Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Allergic: Difficulty Breathing-Severe, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Severe, Systemic: Chest Tightness / Heaviness / Pain-Severe, Systemic: Flushed / Sweating-Medium, Systemic: Hyperventilation-Medium, Additional Details: patient's husband says pt was admitted to hospital with burning in chest, heart, throat swelling, anxiety and trouble breathing.
Patient given 2nd dose 1 week before the due date; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient given 2nd dose 1 week before the due date) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient given 2nd dose 1 week before the due date). On 04-Feb-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient given 2nd dose 1 week before the due date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  No treatment information was provided by the reporter.
loss of taste and can not taste certain foods / 50% less taste; trouble sleeping; nausea; headache; chills; fever; This case was reported by a consumer via call center representative and described the occurrence of difficulty sleeping in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 24th October 2020, the patient received the 2nd dose of Shingrix (intramuscular). On 24th October 2020, less than a day after receiving Shingrix, the patient experienced difficulty sleeping, nausea, headache, chills and fever. On an unknown date, the patient experienced taste loss. On an unknown date, the outcome of the difficulty sleeping, nausea, headache, chills and fever were recovered/resolved and the outcome of the taste loss was not recovered/not resolved.   It was unknown if the reporter considered the difficulty sleeping, nausea, headache, chills, fever and taste loss to be related to Shingrix.  Additional details were provided as follows: Within 6 hours of receiving the vaccine the patient had fever, chills, headache, nausea and trouble sleeping and these events lasted about 2 and half days and then resolved.  Few days after receiving the second dose she had a loss of taste and could not taste certain foods and reported that she had 50 percent less taste and this was still ongoing at the time of reporting. The patient did not have lot number or expiration date information to provide.  The reporter did not consent to follow-up.
Pain around PEG tube site and nutrition assessment. PEG tube placed day before. Dementia, fatigue and abdominal pain
This case was reported by a other health professional via regulatory authority and described the occurrence of headache in a 16-year-old female subject who received CERVARIX. Concomitant products included CERVARIX. In June 2012, the subject received CERVARIX (Intramuscular). On an unknown date, unknown after receiving CERVARIX, the subject experienced headache (serious criteria clinically significant/intervention required), ear pain (serious criteria clinically significant/intervention required), deafness (serious criteria clinically significant/intervention required), tinnitus (serious criteria clinically significant/intervention required), sensation of block in ear  (serious criteria clinically significant/intervention required), dizziness  (serious criteria clinically significant/intervention required), cognitive disorder (serious criteria clinically significant/intervention required), sleep disorder (serious criteria clinically significant/intervention required), constipation (serious criteria clinically significant/intervention required), diarrhoea (serious criteria clinically significant/intervention required), menstruation irregular (serious criteria clinically significant/intervention required), generalised aching (serious criteria clinically significant/intervention required), malaise (serious criteria clinically significant/intervention required), tremor (serious criteria clinically significant/intervention required), sensory aberrations (serious criteria clinically significant/intervention required), nystagmus (serious criteria clinically significant/intervention required), weakness (serious criteria clinically significant/intervention required), abdominal pain (serious criteria clinically significant/intervention required), queasy (serious criteria clinically significant/intervention required), orthostatic dysregulation (serious criteria clinically significant/intervention required), and pain in jaw (serious criteria clinically significant/intervention required). On an unknown date, the outcome of the headache, ear pain, deafness, tinnitus, sensation of block in ear, dizziness, cognitive disorder, sleep disorder, constipation , diarrhoea, menstruation irregular, generalised aching, malaise, tremor, sensory aberrations, nystagmus, weakness, abdominal pain, queasy, orthostatic dysregulation and pain in jaw were unknown. The reporter considered the headache, ear pain, deafness, tinnitus, sensation of block in ear, dizziness, cognitive disorder, sleep disorder, constipation, diarrhoea, menstruation irregular, generalised aching, malaise, tremor, sensory aberrations, nystagmus, weakness, abdominal pain, queasy, orthostatic dysregulation and pain in jaw to be related to CERVARIX.
Erythema, warmth and tendenress near injection site, steadily worsening since vaccine administration 4 days ago.
The day after getting the vaccine there was a red spot on the inner part of the right arm. It was oval in shape and the diameter of a half dollar. It was hot to the touch and sensitive. By the next day it was gone. It came back a week later on a different part of the same arm. More towards the center of the arm and more circular. Still hot to the touch and sensitive
After receiving the maderna vaccine two weeks ago , I have notice that I now experience outdoor allergies that I never had before.   I have itchy eyes and running noses when outside, when inside I seem to have no side effects.
Progressive multiple Joint pain  Pain in right knee knee more than the left knee  Left shoulder pain where the vaccine was injected  Feeling tired all the time  Increase in blood pressure  Sudden hair loss, became obvious approximately 6 months ago